Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)

OTCMKTS · Delayed Price · Currency is USD
2.175
-0.250 (-10.31%)
At close: May 22, 2026
Market Cap7.89B -0.4%
Revenue (ttm)6.13B +4.9%
Net Income504.05M +18.9%
EPS0.19 +19.4%
Shares Out n/a
PE Ratio15.64
Forward PE16.36
Dividendn/a
Ex-Dividend Daten/a
Volume202
Open2.175
Previous Close2.425
Day's Range2.175 - 2.175
52-Week Range1.955 - 3.500
Beta0.41
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About SFOSF

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, car... [Read more]

Sector Healthcare
Founded 1994
Employees 40,603
Stock Exchange OTCMKTS
Ticker Symbol SFOSF

Financial Performance

In 2025, SFOSF's revenue was 41.66 billion, an increase of 1.45% compared to the previous year's 41.07 billion. Earnings were 3.37 billion, an increase of 21.69%.

Financial numbers in CNY Financial Statements

News

Shanghai Fosun Pharmaceutical (Group) Quarterly report: Q1 2026

Shanghai Fosun Pharmaceutical (Group) has published its Q1 2026 quarterly earnings report on April 28, 2026.

5 weeks ago - Filings

Shanghai Fosun Pharmaceutical (Group) Annual report: H2 2025

Shanghai Fosun Pharmaceutical (Group) has published its H2 2025 annual report on March 24, 2026.

2 months ago - Filings

Shanghai Fosun Pharmaceutical (Group) Quarterly report: Q3 2025

Shanghai Fosun Pharmaceutical (Group) has published its Q3 2025 quarterly earnings report on October 28, 2025.

7 months ago - Filings

Shanghai Fosun Pharmaceutical (Group) Slides: Q3 2025

Shanghai Fosun Pharmaceutical (Group) has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.

7 months ago - Filings

Shanghai Fosun Pharmaceutical (Group) Quarterly report: H1 2025

Shanghai Fosun Pharmaceutical (Group) has published its H1 2025 quarterly earnings report on August 26, 2025.

10 months ago - Filings

Shanghai Fosun Pharmaceutical (Group) Slides: H1 2025

Shanghai Fosun Pharmaceutical (Group) has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 26, 2025.

10 months ago - Filings

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

3 years ago - Reuters

Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos Health will provide Full-Service Commercial support through its Syneos One team...

3 years ago - TheFly

Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment

4 years ago - Forbes

China's health-care sector may be next to face regulatory crackdown, says economist

Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...

5 years ago - CNBC International TV

Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations

Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.

5 years ago - CNBC